Cardiovascular Disease

From type 2 diabetes to chronic yeast infection, we have picked the top 7 FDA-approved drugs every primary care physician should know about from the second quarter.

Less than 7% of the US population has "optimal" cardiometabolic health, with declines over 20 years significantly affecting racial/ethnic populations.

Three-quarters of stroke patients in a Swiss registry had at least 1 undiagnosed risk factor at the time of the event, most commonly hyperlipidemia or hypertension.

Slide Show: The AHA added sleep duration to its Life's Simple 7 cardiovascular health construct and updated sections on diet, lipids, blood glucose and smoking.

Statin-treated patients at high atherosclerotic risk experienced significantly slower progression of arterial stiffness vs those not taking statins in a cohort of more than 5000 patients.

The FDA ban yesterday on Juul vaping devices and nicotine e-liquid pods drew praise from the American Medical Association, American Thoracic Society, American Lung Association, among others.

Elements of proper blood pressure measurement technique may seem picayune, but skipping them may cost you - here's how much.

Exercise began as foraging for survival for our hunter/gatherer forbears and is no less essential in our contemporary age of sitting and screen time. Take a quick trip through history.

How prevalent is NAFLD worldwide? What is the preferred treatment? And more questions to test your NAFLD knowledge.

A new study found patients with T1D and T2D had a greater risk for stenotic lesions, whereas risk for valvular regurgitation was lower in those with T2D.

ADA 2022: Reduction in risk of progression to type 2 diabetes of 60% was seen in STEP program clinical trial participants with overweight or obesity.

ADA 2022: The protective effect of finerenone on cardiovascular and renal outcomes was not affected by initial HbA1c levels or T2D duration in analysis of data from the FIDELITY pooled cohort.

ADA 2022: In a real-world study of nearly half a million adults with T2D followed for 5 years, the SGLT-2 inhibitor surpassed both other classes used in routine clinical care.

ADA 2022: Tirzepatide, a GIP/GLP-1 receptor agonist, reduced a composite of kidney events in patients with type 2 diabetes and at increased cardiovascular risk in an analysis of SURPASS-4.

The first study of its kind found that intensive blood pressure control may be most beneficial in older adults with life expectancy greater than 3 years vs less than 1 year.

One-half of more than 600 000 patients with ASCVD were not prescribed statins at all and only 22.5% were taking a high intensity statin, according to a recent study.

Among more than 3000 participants with prediabetes, neither metformin or lifestyle change reduced risk for CV events over 21 years according to Diabetes Prevention Program Outcomes Study investigators.

In adults with type 2 diabetes seen in primary care, lowering glucose substantially during the first 12 months post-diagnosis decreased risk for future MACE.

The patient is a young man who presents after resolution of several hours of chest pain. He is recovering from a lower GI illness and still taking Cipro. What's your Dx?

New study presented at Heart Rhythm 2022 showed applying AI to an Apple Watch ECG can effectively identify LV dysfunction in a nonclinical setting.

Seven risk factors accounted for 85% of the risk of first acute myocardial infarction in young adults in a new study.

High-level results show the trial met its composite primary endpoint, lowering risk of CV death or worsening disease in patients with HFmrEF/HFpEF.

Black patients hospitalized with atrial fibrillation were 25% less likely to receive oral anticoagulants upon discharge according to a large national registry study.

PCPs and internists accounted nationally for 57% of SGLT2i and 52% of GLP1RA prescriptions in 2020, more than any other specialty, according to new research.

The cardiac myosin inhibitor is the only treatment that targets the pathophysiology of the disease, improving patient function and symptoms.

USPSTF states low-dose aspirin should be considered for CVD prevention on a case-by-case basis in adults aged 40-59 yrs with a 10% or greater 10-year CVD risk.

Dylan Steen, MD talks about several SuperWIN results that caught him happily by surprise and suggest plenty of room for follow-up research.

NAFLD is a key risk factor for ASCVD and widely underdiagnosed. This Guideline Topline summarizes new AHA warnings, guidance.

The NDA for daprodustat, a novel investigational agent, is based on data from pivotal ASCEND program clinical trials.

Patients who received a low-dose 3-drug combination pill achieved time at BP target of 64% vs the usual care group result of 43% in a post-hoc analysis of TRIUMPH.